Data from Pharmawand - Curated by Toby Galbraith - Date added 07 August 2017
Jazz Pharmaceuticals plc announced that the FDA has approved Vyxeos (daunorubicin and cytarabine) liposome for injection for the treatment of adults with two types of Acute Myeloid Leukemia (AML), a rapidly progressing and life-threatening blood cancer. Vyxeos is indicated for the treatment of adults with newly-diagnosed t-AML or AML-MRC. Vyxeos is the first new chemotherapy advance in more than 40 years for adults with newly-diagnosed therapy-related AML or AML with myelodysplasia-related changes.
Designed with Jazz's CombiPlex proprietary technology, Vyxeos is a unique liposomal formulation that delivers a fixed-ratio of daunorubicin and cytarabine to the bone marrow that has been shown to have synergistic effects at killing leukemia cells in vitro and in animal models. Vyxeos is the first product developed with the company's proprietary CombiPlex platform, which enables the design and rapid evaluation of various combinations of therapies.
Comment: Vyxeos comprising daunorubicin and cytarbine — has shown that given in a single formulation patients livde about three and a half months longer then when administered separately.